|
The threat remains but we can’t afford to fight it
Remember the NASEM “study” in 2020 that recommended that the FDA consider that compounded BHT be considered “demonstrably difficult” and hence illegal to compound?
As you probably already know, the “study” was not based on science or evidence. It was based on subjective opinion of the “experts” of the Academy and was written with the pre-drawn conclusions of the FDA before the authors even started. This threat still exists.
In 2021, APC started the “Save cBHT” campaign. You can learn more about that at compounding.com. Since 2021, this campaign has reached 25,000,000 patients, prescribers and physicians, has engaged with more than 300,000 stakeholders and has messaged every member of congress about the importance of cBHT.
This is a proactive campaign by APC. I’m sure all of you agree with the old saying: An ounce of prevention is worth a pound of cure. So, we can either continue being proactive and getting patients and lawmakers to contact the FDA before it acts, or we can sit back and be reactive, waiting for the agency to act first.
Unfortunately, this campaign is broken, and we need your help. Our budget for 2022 is $850,000 but we are nowhere near close to that. If we don’t receive funding fast, this campaign will shut down in July 2022. The profession cannot afford to have that happen and neither can your businesses nor your patients.
The threat is real. How many of us will go out of business if we lose the ability to compound cBHT? How many of our patients will suffer irreparable harm from loss of this therapy? Help us fight the threat. Contribute today at compounding.com
• • •
David Miller is APC’s president and the managing co-owner of Keystone Compounding Pharmacy in Grand Rapids, Michigan. You can reach him at drdave@keystonepharm.com.
| 
